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Suntmary 
The activation  of T lymphocytes,  both in vivo and in vitro, induces the expression of CD69. 
This molecule, which appears to be the earliest inducible cell surface glycoprotein acquired during 
lymphoid activation, is involved in lymphocyte proliferation and functions as a signal transmitting 
receptor in lymphocytes, natural killer (NK) cells, and platelets. To determine the structural basis 
for CD69 function, the cDNA coding for CD69 was isolated by a polymerase chain reaction-based 
strategy using oligonucleotides deduced from peptide sequences of the purified protein. The isolated 
cDNA exhibited a single open reading frame of 597 bp coding for CD69, and predicted a 199-amino 
acid protein of type II membrane topology, with extracellular (COOH-terminal), transmembrane, 
and intracellular domains.  The CD69 clone hybridized to a 1.7-kb mRNA species, which was 
rapidly induced and degraded after lymphocyte stimulation, consistent with the presence of rapid 
degradation signals at the 3' untranslated region. Transient expression of the polypeptide encoded 
by CD69 cDNA in COS-7 cells demonstrated that it presented properties comparable to native 
CD69 protein. The CD69 gene was regionally mapped to chromosome 12 p13-p12 by both 
somatic cell hybrid DNA analysis and fluorescence  in situ hybridization coupled with GTG banding 
(G bands by trypsin using Giemsa). Protein sequence homology search revealed that CD69 is 
a new member of the Ca2+-dependent  (C-type) lectin superfamily of type II transmembrane 
receptors, which includes the human NKG2, the rat NKR-P1, and the mouse NKR-P1 families 
of NK cell-specific genes. CD69 also has structural homology with other type II lectin cell 
surface receptors, such as the T cell antigen Ly49, the low avidity immunoglobulin E receptor 
(CD23), and the hepatic asialoglycoprotein receptors. The CD69 protein also shares functional 
characteristics with most members of this superfamily, which act as transmembrane signaling 
receptors  in early phases of cellular activation. 
T 
he activation ofT lymphocytes by antigens or mitogens 
initiates a coordinate up- and downregulation of the ex- 
pression of a wide number of known genes (1). The genes 
that are induced during the early phase of cell activation are 
also known as immediate-early genes. To this group belong 
several protooncogenes, such as c-fos, c-jun, or c-re?r, and genes 
encoding molecules involved in signaling events, induding 
triggering molecules,  growth  factors,  and some cytokine 
receptors  (1, 2). 
The CD69 molecule (3), also designated as activation in- 
ducer molecule (AIM) (4), early activation  antigen (EA-1) 
(5), Leu-23 (6), or MLR-3 (7) antigens, is a phosphorylated 
disulfide-linked 27/33-kD homodimeric protein (8). This an- 
tigen seems to be the earliest inducible cell surface glycopro- 
tein and is synthesized de novo and expressed upon T lym- 
phocyte activation  with a wide variety of stimuli, such as 
anti-CD3/TCR and anti-CD2 mAbs,  activators of protein 
kinase C, or PHA (4, 5, 9,  10). The expression of CD69 
by IL-2-activated NK cells parallels the acquisition  of lytic 
activity by these cells (6). CD69 is undetectable on the plasma 
membrane of most circulating PBL; however, this molecule 
is expressed by a large fraction of T cells in the inflammatory 
infiltrates  of several human diseases (11, 12), as well as by 
a small percentage of resident T and B cells in different normal 
lymphoid tissues (13). In this context, CD69 expression on 
thymocytes has been associated with the acquisition  of im- 
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cell types, including platelets and epidermal Langerhans cells, 
also express  the CD69 molecule (16, 17). 
The CD69 glycoprotein functions as a signal-transmitting 
receptor in different cells. In T  cells, the signals  triggered 
by CD69 antibodies include rise ofintracellular calcium con- 
centration, expression of the IL-2R c~ subunit (CD25), syn- 
thesis of different cytokines, such as IL-2, TNF-ot, and IFN-% 
and cell proliferation (4,  9,  18-20).  Furthermore, the trig- 
gering of T cells through the CD69 activation pathway en- 
hances the binding activity  of transcription factor AP-1, which 
plays a key regulatory role in the initial steps of cell activa- 
tion (21). Likewise, CD69 also acts as a triggering molecule 
on NK cells and platelets: CD69 antibodies are capable  of 
inducing target cell lysis by IL-2-activated NK cells (22, 23), 
and of triggering platelet aggregation, Ca  2  + influx, and hy- 
drolysis of arachidonic acid (16). The possible  coupling of 
CD69 with a GTP-binding protein has also been reported (24). 
In an attempt to understand the molecular basis for the 
CD69 functions, the cDNA encoding this protein was cloned 
and its nucleotide sequence determined. We herewith report 
that CD69 protein is a type II membrane protein with a C-type 
animal lectin domain.  Comparative protein sequence ho- 
mology indicates that CD69 is a member of a gene super- 
family of type II membrane proteins that includes a wide 
number of mouse, rat,  and human NK cell-specific  genes 
that, like CD69, function as signal-transmitting receptors. 
Materials and Methods 
mAbs.  The different anti-CD69 TP1/8,  TPl/55, and FAB/1 
mAbs, directed to extracellular antigenic determinants of CD69, 
have been previously described (8). The CH/2 mAb is specific  for 
an intracellular CD69 epitope (8). Monodonal Ig (Igl,K) from the 
myeloma  line P3X63 was inchded as negative  control in some assays. 
Purification of CD69  Protein.  The  anti-CD69  FAB/1 mAb 
(IgG1,K) (8) was purified from ascites fluids by protein A af~nity 
chromatography and coupled to CNBr-activated Sepharose Cb4B 
(Pharmacia, Uppsala, Sweden) at 2 mg/ml. 
PBL were obtained from buffy coats by Ficoll-Hypaque (Phar- 
macia) centrifugation. Activation of PBL was carried out by cul- 
turing 2  x  10  ~ cells/ml in the presence of PMA (10 ng/ml) and 
soluble anti-CD3 SPV-T3b mAb for 24 h (4). Activated PBL (2 
x  10  s cells/m1) were lysed in a buffer containing 20 mM Tris- 
HC1, pH 8.0, 1% Triton X-100, 5 mM iodoacetamide, 1 mM PMSF, 
0.2 U/ml trypsin inhibitor of aprotinin, and 0.025% NAN3. After 
30 min at 4~  the lysate  was clarified  by centrifugations at 1,000  g 
for 10 rain followed by 50,000 g for 1 h. Preparative scale im- 
munoaffinity isolation was performed by passing 50 ml of lysate 
over sequential glycine-quenched  Sepharose CL-4B and anti-CD69 
FAB/1- Sepharose Cb4B columns at a flow rate of 1 ml/min. The 
FAB/1 column was washed with a five-column  bed volume of 25 
mM Tris-HC1, pH 9.5, 1.5 M NaC1, 0.5% Triton X-100, 1 mM 
iodoacetamide, 0.5 mM PMSF, and 0.025% NAN3. The column 
was then washed with 3 vol of 100 mM ammonium acetate, pH 
6.0, 25 mM N-octyl-/~-glucopyranoside  (OG). The CD69 protein 
was eluted with 3 vol of 100 mM ammonium acetate, pH 2.5, 
25 mM OG at a flow rate of 0.3 ml/min. Fractions (1 ml) were 
collected into tubes containing 50 #1 of 1 M ammonium bicar- 
bonate. Homogeneity of immunoafl:mity-purified  protein was as- 
sessed by SDS-PAGE and silver staining. 
Protein Digestion, Peptide Purification, and Sequencing.  Approxi- 
mately 200 pmol (1 ml) of purified protein was dissolved  with 200 
#1 of 1 M Na2HPO4 and denatured at 100~  for 5 min. After 
cooling, N-glycanase enzyme (Genzyme Corp., Cambridge, MA) 
was added and incubated for 16 h at 37~  After incubation, the 
sample was concentrated, washed three times with 0.5 ml of 0.1% 
SDS, and reduced in volume to near dryness. The sample was then 
diluted up to 50 #1 with sample buffer containing 0.5%  2-ME 
without SDS and alkylated with the addition of I/zl of 4-vinyl- 
pyridine and run on SDS-11% PAGE. 
In situ digestion of the protein in the polyacrylamide  gel matrix 
was done by incubating the gel pieces with endoproteinase Lys-C 
(Promega Biotec, Madison, WI) for 20 h at 37~ 
The resulting Peptides were then subjected to  narrow-bore, 
reverse-phase HPLC. The first step of peptide purification  was made 
on a Vydac  C4 (2.1  x  250-mm) column run in 0.1% TFA. Frac- 
tions of  pure peptide  were subjected  to automated  Edman sequencing 
on a protein sequencer (477A; Applied Biosystems,  Inc., Foster  City, 
CA) on line to the 120A Separation system. 
cDNA Cloning.  Degenerated sense and antisense oligonucleo- 
tides, deduced from the amino acid sequences of two Lys-C Pep- 
tides (Fig. 1), were used as primers to achieve  PCK (25) on a pool 
of reversely transcribed KNA from human PBL activated with 10 
ng/ml of  PMA at various  time points (30 min to 48 h). Amplification 
was carried out for 35 cycles (l-rain denaturation at 95~  l-rain 
annealing at 50~  and 1.5-min elongation at 72~  using an RNA 
PCR kit (Perkin Elmer Cetus, Norwalk, CT).  Amplification of 
the 3'  end of CD69  cDNA was achieved by PCK on reverse- 
transcribed RNA from PMA-activated  PBL essentially  as described 
(26), using the internal primer AIM 1 (5'-AGGAACCTGGTC- 
ACCCATGG-Y, nucleotides [nt] 1 521-540). To isolate the 5' end 
of CD69 cDNA, random-primed first-strand cDNA was synthe- 
sized  from  PMA-activated  PBL  poly(A) +  KNA  and  poly- 
adenylated  according to a protocol previously described (27), then 
the 5' cDNA end was amplified as described (26), using the in- 
ternal primer AIM 3 (5'-TTCCATGCTGCTGACCTCTGT-Y,  nt 
616-636 of the [-] strand). To verify the nucleotide sequence of 
the CD69 open reading frame (OR.F), two independent PCR were 
performed on PMA-activated  PBL KNA using the primers AIM 6 
(5'-GAGCTCCAGCAAAGACTTTC-3  ~ nt  12-31) and  AIM  7 
(5~  nt  686-705 of the  [-] 
strand) from the 5'- and Y-untranslated regions. Amplification  was 
carried out for 35 cycles (1-min denaturation at 95~  1-min an- 
nealing at 58~  and 1.5-min  elongation  at 72~  The amplification 
products of PCRs were purified from agarose gels by using the 
Gene Clean kit (Bio 101 Inc., La Jolla, CA) and cloned into pCK 
II plasmid (Invitrogen Corp., San Diego, CA). 
DNA sequencing was performed by the dideoxy termination 
method  (28) either  by  subcloning  restriction  fragments  into 
Bluescript vectors or by direct oligonucleotide-primed DNA se- 
quencing with internal primers when no convenient  restriction sites 
were available. 
Northern Blot Hybridization Analysis.  Total  KNA was isolated 
from human PBL, either untreated or treated with 10 ng/ml of 
PMA at various time points (0.5, 1, 3, 6,  12, 24, and 48 h) by 
the guanidine isothiocyanate  method (29). A total of 10-20 #g of 
RNA of each sample was run on 1% formaldehyde-agarose  gels 
and transferred  onto nitrocellulose  membranes. Hybridizations  were 
performed using the cloned 197-bp fragment, obtained by PCK 
1 Abbreviations used in this paper: nt, nucleotide;  ORF, open reading frame. 
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probe. To normalize by laser densitometry the CD69 mRNA ex- 
pression, a 32p-labded 13-actin cDNA probe was used as control. 
Chromosome Mapping of the CD69 Gene.  Chromosomal  local- 
ization of the CD69 gene by PCR was performed on DNA from 
interspecies hamster-human  somatic cell hybrids  (BIOSMAP  TM 
Somatic  Cell  Hybrids  PCRable  TM  DNAs;  BIOS  Corp.,  New 
Haven, CT) using  the AIM 1 and 3 primers.  The specificity of 
PCR products  was confirmed by hybridization  with a genomic 
CD69 probe, which included  the sequence between the AIM 1 
and 3 oligonucleotides. 
The regional  localization of the CD69 gene was assessed by 
fluorescence  in situ hybridization with an EMBL3 phage containing 
a 15-kb genomic CD69 DNA. The X-h CD69-1 phage, containing 
a 15-kb genomic insert,  was isolated from a human  genomic li- 
brary constructed in the EMBL3 phage vector, as will be described 
elsewhere. The genomic done was labeled by nick translation with 
digoxigenin-11-dUTP  (Boehringer Mannheim,  Mannheim,  Ger- 
many) and diluted in hybridization buffer (50% formamide, 10% 
dextran sulphate, 2 x  SSC, and 50 mM phosphate, pH 7.0). After 
heat denaturation,  4 ng/gl of labeled probe was preannealed with 
a 500-fold excess of sonicated human  placental DNA for 1 h at 
37~  and hybridized overnight to denatured metaphase chromo- 
somes from a normal male. Hybridization,  washings, and detec- 
tion with rhodamine-conjugated  antibodies were performed as de- 
scribed (30). Chromosomes  were counterstained  with 75 ng/ml 
of 4'-6-diamino-2-phenylindole (DAPI) in antifade medium. After 
the fluorescent microscopy, GTG banding  was performed as de- 
scribed (30). 
FACS  | Analysis.  Fluorescence flow cytometry analysis was per- 
formed on a FACScan  |  cytofluorometer (Becton Dickinson & Co., 
Mountain  View, CA). Cells were incubated at 4~  with 100 gl 
hybridoma culture supernatants, followed by washing and labeling 
with fluorescein isothiocyanate-labeled goat anti-mouse Ig (Pierce 
Chemical Co., Rockford, IL). Data were collected in a logarithmic 
scale, and percentage of positive cells was obtained by substracting 
the background given by the mouse myeloma P3X63. 
Transfection of CO$ Cells, Indirect Immunofluorescence, and Immu- 
no~ecipitation.  To construct the CD69 expression vector (pAIMI- 
neo), a recombinant pCRII plasmid harboring the complete CD69 
ORF and part of the 5' and 3' adjacent sequences (nt 12-705) was 
partially digested with BstxI and the resultant  700-bp fragment 
ligated to the plasmid pcDNAI-neo (Invitrogen Corp.) downstream 
of the cytomegalovirus promoter. The orientation of the insert was 
tested by restriction  enzyme analysis. 
For transient  expression of CD69, monolayers of COS-7 cells 
were transfected with pAIMI-neo by the diethylaminoethyl-dextran 
method (31). Plasmid pcDNAI-neo was also included in the trans- 
fection as a control. 
Transfected COS ceils were grown on glass coverslips and cells 
were fixed in 3.7% formaldehyde in PBS for 10 min at room tem- 
perature. Cells were incubated with the primary antibody for I h 
at 37~  rinsed in Tris-buffered saline, and stained with the appro- 
priate  dilution  of the  secondary  antibody  (FITC-labded  goat 
anti-mouse Ig; Pierce Chemical Co.). TPl/8 and TPl/55 mAbs 
were used as primary antibodies. Cells were observed using an Op- 
tiphot photomicroscope (Nikon Inc., Instr. Group, Melville, NY). 
Activated PBL, and transfected COS-7 cells harvested 72 h after 
transfection, were radioiodinated in solution with chloroglycoluril 
(Iodogen; Pierce Chemical Co.). For immunoprecipitation,  equal 
amounts of input radioactivity were mixed with 30/zl of different 
purified  anti-CD69  mAb  directly  conjugated  to  Sepharose (2 
mg/ml). Immunoprecipitates were processed as previously described 
(4) and samples were subjected to SDS-PAGE on 12% gds either 
under  reducing  or nonreducing  conditions. 
Results 
Isolation and Characterization of CD69 cDNA.  The CD69 
glycoprotein was purified from PMA-activated human PBL 
by mAb affinity chromatography. Homogeneous CD69 pro- 
tein was obtained as determined by SDS-PAGE followed by 
silver staining (Fig.  1 A).  The purified protein was treated 
with N-glycanase, digested with Lys-C endopeptidase,  and 
the resulting peptides were separated by reverse-phase HPLC 
and subjected to amino acid micro-sequencing. A total of 38 
residues were determined from four independent peptides (Fig. 
1 B). Degenerated sense and antisense oligonucleotides (Fig. 
1 C) based on two Lys-C peptides (Fig. 1 B, underlined) were 
designed and used as primers to carry out PCR on reversely 
transcribed  poly(A) + RNA from a pool of PBL activated 
with PMA at different times (30 min to 24 h) (see below, 
Fig. 5 A). A DNA fragment of 197 bp was amplified using 
the oligonucleotides 3.1 +  and 4.2-, whereas no amplification 
product was obtained with  the oligonucleotides 4.1+  and 
3.3-.  The specificity of the 197-bp product was verified by 
a second PCR performed on the first PCR products, using 
the oligonucleotide 3.2 +, which overlaps oligonudeotide 3.1+, 
and the oligonucleotide 4.2-  (Fig.  1 C). The specific prod- 
ucts of both PCRs were doned and sequenced. The full-length 
cDNA was obtained by PCR after the rapid amplification 
of cDNA 5' and 3' ends (RACE) protocols (Fig.  1 D). The 
complete nucleotide sequence of the  1.7-kb CD69 cDNA 
and the amino  acid sequence of the translation  product is 
shown in Fig.  2. 
To confirm the predicted amino acid sequence of the CD69 
translation product, two additional independent PCRs were 
performed using primers from the 5'- and 3'-untranslated se- 
quences adjacent to the ORE  No polymerase-induced mu- 
tations were observed on these cloned PCR products.  The 
ORF extended from nt 82 to 678, and contained the amino 
acid sequences of the four different Lys-C peptides. ORF was 
preceded by a 5'-untranslated  region of 81 bp and followed 
by a Y-untranslated region of 1,023 bp, which contained three 
poly(A) and multiple  rapid degradation  signals  (Fig.  2). 
Expression of CD69 Antigen in COS Cells.  To confirm that 
the cDNA isolated was encoding CD69 antigen, COS-7 cells 
were transfected with the CD69 ORF, which was placed under 
the control of the cytomegalovirus promoter. Transfected cells 
reacted  with  several  anti-CD69  mAbs  as  shown  by  im- 
munofluorescence (Fig. 3 A). Furthermore, immunoprecipi- 
tation with mAb directed against extracellular and intracel- 
lular epitopes of the CD69 antigen (8) from 12sI externally 
labeled  transfected  COS-7  cells  yielded  two bands  under 
reducing conditions, which corresponded to the 27- and 33- 
kD bands of the native CD69 precipitated from activated PBL 
(Fig. 3 B). Under nonreducing conditions, immunoprecipi- 
ration with anti-CD69 mAb yielded a single band of 60 kD, 
which is the expected molecular mass of the disulfide-linked 
CD69 homodimer (Fig. 3 B). These results demonstrate that 
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the cDNA-encoded CD69 protein possesses identical prop- 
erties as native  CD69 antigen. 
Predicted Amino  Acid  Sequence of the  CD69  Translation 
Product.  The deduced amino add sequence  of the CD69 OILF 
corresponded to a polypeptide of 199 residues with a predicted 
molecular weight of 22,545, which is in agreement with the 
previously reported molecular weight of deglycosylated  CD69 
protein (22,000-24,000)  (6, 8). This polypeptide was devoid 
of NH2-terminal hydrophobic signal peptide but contained 
a transmembrane domain of 26 amino acids as predicted by 
hidrophobicity analysis (32). (Fig. 2). These features on the 
primary structure of CD69 indicated that it is a type II integral 
membrane protein  and is  therefore  composed of a  NHz- 
terminal cytoplasmic domain of 38 residues, a single trans- 
membrane region of 26 residues, and an extracellular COOH- 
terminal domain of 135  amino acids. 
A putative site was found for N-linked glycosylation  in 
the extracellular domain of CD69 (Fig. 2). The existence of 
this N-linked glycosylation site is in agreement with previous 
results demonstrating, by both glycosidase and tunicamycin 
treatments, the presence  of N-linked glycosylation  in the CD69 
protein (6,  8).  Several potential phosphorylation sites for 
serine/threonine kinases, PKC, and casein kinase II were found 
within the cytoplasmic tail (Fig. 2), in accordance with the 
constitutive Ser/Thr phosphorylation of CD69 in both ma- 
ture thymocytes and activated T  lymphocytes (6,  14, 33). 
CD69 Is a Member  of  the C-Type  Animal Lectin Superfamily. 
Comparison of the predicted amino acid sequence with the 
SWISSPROT and EMBL databases using the search algorithm 
FASTA (34) indicated that CD69 has homology with pro- 
teins  of the animal C-type lectin superfamily,  which also 
possess the unusual type II membrane orientation (Fig. 4). 
Most  markedly,  computer-aided  comparisons  using  the 
BESTFIT program revealed that CD69 has strong amino acid 
sequence similarity ranging from 44 to 48% with the human 
NKG2 (35), and the rat and mouse NKR-P1 protein families 
(36, 37).  It was found that CD69 protein is also homolo- 
gous to  the human and mouse low affinity  IgE receptor 
(CD23) (38-40), the hepatic asialoglycoprotein receptor (41), 
and the mouse T  cell antigen Ly49 (42,  43).  The highest 
sequence similarity was confined mainly to the C-type lectin 
domain, which covers a stretch of 116 amino adds of the CD69 
polypeptide,  the most striking feature being the presence of 
12 invariant residues (Fig. 4). Particularly  important is the 
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Figure  2.  CD69  cDNA  nucleotide  sequence  and 
predicted amino acid sequence. The transmembrane do- 
main is double underlined, and potential polyadenylation 
signals are single underlined. Potential rapid degradation 
signals are in boxes. Putative N-linked glycosylation sites 
are indicated  by asterisks  and phosphorylation rites are PKC 
and casein kinase II (CK2). These sequence data have been 
submitted  to the EMBL Data Library under accession 
number Z22576. 
conserved placement of six of the Cys residues (Fig. 4), which 
appear to be involved in disulfide bonds (41, 44). Although 
there are no long continuous stretches of invariant residues, 
almost all of the essential  residues conforming the C-type 
carbohydrate recognition domain (41) are present at approxi- 
mately the same spacing.  CD69 also showed certain degree 
of similarity with the transmembrane and cytoplasmic regions 
of other C-type lectin cell surface receptors expressed by leu- 
kocytes,  such as the NKG2  and NKR-P1  members. 
CD69 mRNA Expression.  The cell surface expression of 
CD69 is almost exclusively restricted to leukocytes and is tran- 
siently induced upon treatment of lymphocytes with several 
mitogenic reagents such as phorbol esters (4). Northern blot 
analysis of RNA from untreated and PMA-treated PBL using 
a specific CD69 cDNA probe showed a PMA-inducible RNA 
species of 1.7 kb, in agreement  with the size of the isolated 
cDNA  (Fig.  5 A). 
The early expression of CD69 protein upon T cell activa- 
tion together with the presence of rapid degradation  signals 
at the 3' untranslated region of the CD69 cDNA led us to 
analyze the induction kinetics of the CD69 mRNA. There- 
fore, PBL were stimulated with PMA at various time points, 
and then the total RNA was subjected to Northern blot anal- 
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ysis with a CD69 cDNA probe  (Fig.  5 B).  In paraUel, the 
surface expression  of CD69  antigen was assessed by flow 
cytometry (Fig.  5 C). CD69 mRNA showed a transient in- 
crease after exposure of cells to PMA. It became detectable 
by 30 min to 1 h, with maximal expression by 6 h, reaching 
a 50-fold increase, and declined thereafter to undetectable levels 
(Fig. 5 B). The surface expression of CD69 antigen displayed 
a slower kinetics compared with that of the mRNA induc- 
tion. It reached a peak by 12 h of PMA treatment,  declined 
partially by 24 h, and then the induced level persisted  for 
at least 48 h (Fig. 5 C). These results indicated that the level 
of CD69 mRNA regulates CD69 protein expression.  Simi- 
larly, Northern blot analysis performed on RNA from different 
cell lines, which were either unstimulated or stimulated with 
PMA for 6 h, showed that the tissue-specific distribution of 
CD69 antigen is regulated  at transcriptional level (data not 
shown). 
Chromosomal Assignment of the CD69 Gene.  The CD69 
gene was located on chromosome 12 by PCR analysis of DNA 
from interspecies hamster-human somatic cell hybrids (Fig. 
6,  and  data  not  shown).  As  observed  in  Fig.  6  A,  an 
amplification  product of 1.1 kb was obtained only in those 
hybrids containing chromosome 12 (lane 4).  The presence Figure 3.  Transient expression of cDNA-encoded CD69 in COS-7 cells. 
(A) Immunofluorescence staining of CD69-tramfected cells with anti-CD69 
TP1/8 and TP1/55 mAbs. The monoclonal Ig from P3X63 myeloma was 
included as negative control. (B) Immunoprecipitation analysis of CD69 
from tramfected COS cells. Lysates from ~2SI-labeled  transf~cted cells with 
pcDNA1-Neo (vector  without  an insert) (lanes  1-3),  transfected  with 
pAIMI-Neo (containing the CD69 OR.F) (lanes 4-6), and PMA-activated 
PBL (lanes 7-9) were precipitated with the following antibodies: P3X63 
as negative control (lanes I, 4, and 7), the anti-CD69 TP1/8  (lanes 2, 
5, and 8), and CH/2 mAbs (lanes 3, 6 and 9) specific for extracellular 
and intracellular epitopes, respectively.  The  samples  were analyzed by 
SDS-12% PAGE under reducing conditions. Precipitates  with the anti- 
CD69 TP1/8 mAb from PMA-activated PBL (lane I0) and from pAIMI- 
Neo-transfected cells (lane I1) were also analyzed under nonreducing con- 
ditions. 
of 1.0-kb intron between oligonucleotides AIM 1 and 3 (data 
not shown) is consistent with the size of the amplified frag- 
ment.  The  specificity  of  the  PCR  product  was  further 
confirmed by Southern blot hybridization (Fig.  6 B). 
To determine  the regional location of the human CD69 
gene, we have performed  fluorescence  in situ hybridization 
on human metaphase chromosomes using a CD69 genomic 
probe. A total of 30 metaphase spreads were analyzed for the 
h ASGRI 
h CD23 
h CD69 
m NKR-PI 
m Ly49 
h NKG2a 
h ASGRI 
h CD23 
h CD69 
m NKR-PI 
m Ly49 
h NKG2a 
h ASGRI 
h CD23 
h CD69 
m NKR-PI 
m Ly49 
h NKG2a 
KV~FC~G ~IyYFVMDR KT~SGCKQ~ QSSSiS~LK~!  i,~D~DELK~  187 
I~E~IT~S  NS~kY~GKER ~T~ESLL~  TSKNSS~LS!~  ~N~M~S  ~ 
HHI~PVNT.. i~..DQN  G~D~U?D  YETGFK~P  EQPDDWYGK~  247 
K~H~GS..  i~I~K  ~I~S~  W..~S~  GEP~S~  ....  2~3 
~''EEH  !~<.*<EPG ~S~<E  ~.~W~ ..........  ~  ~ 
~rTK~ISSS~  ~S~SD  ~I~S~  r~SDWS  ..........  I~  ~82 
LVVP..SDSC  '~SYDNKK  KD~IDNRP  SKLALNT  ..........  GKY  225 
i~  ....  sPss  ~I~V~RNSSH  ~Tvr~A  ~KHE~I<D ...........  SD  ~8~ 
.SQGED~M  RGSGRWNDAF L~DR~GA~  DRLAT  287 
￿9 ..  S~K~F. ~KN~SSME  ~EK~.~  I N~Y~  199 
DTEK~S~S.  VSQD~ES  [.~DsDNI.~ Q~L~  215 
NIRDGG~ML.  ~SK~LDNGN  [~DQVFI  .C~i  I G~LD  258 
NA.  ELN~AV. ~QVNRLKSAQ  [~GSSII.YH~ KHKL.  233 
Figure 4.  Sequence  alignment of 
the  lectin-like domains  of CD69 
protein and several other members 
of the supergene family. The amino 
acid positions within each sequence 
are shown.  Filled circles indicates 
positions where the residue is highly 
conserved.  The  six invariant Cys 
residues are enclosed within black 
boxes. Identifies between CD69 and 
other C-type lectins are shaded; (h) 
human,  and (ra) mouse. 
542  Molecular Cloning of the CD69  Activation Antigen Figure 5.  Analysis  of  human CD69 mRNA. (A) Northern blot anal- 
ysis of RNA from untreated (lane - ) and PMA-treated  PBL (lane + ) 
with a 3zP-hbeled  CD69-cDNA fragment  spanning  nt 482-678. Positions 
of the ribosomal  28S and 18S RNA are indicated  on the left. (B) Induc- 
tion kinetics  of  CD69 mRNA. PBL vat-re  stimulated  with PMA (10 ng/ml) 
at various time points (30 min, and 1, 3, 6, 12, 24, and 48 h), and the 
total RNA of each  sample  was prepared  and subjected  to Northern blot 
analysis with the same CD69 cDNA probe described  above. A •-actin 
cDNA probe was used as a control for loading amounts. (C) Diagram- 
matic representation  of the induction  kinetics  of CD69 mKNA and pro- 
tein. Laser densitometry  giving corrected  scanning units of the CD69 
mRNA expression  normalized  to the B-actin control  gene is represented 
by failed  circles.  Surface  expression  of  CD69 protein  analyzed  by flow  cytom- 
etry is represented  by open squares. (MFI), mean fluorescence  intensity. 
presence of rhodamine fluorescent spots. As illustrated in Fig. 
6 C, hybridization was specific and the signal was clearly de- 
tected on the short arm of chromosome 12, on bands p13- 
p12  based on GTG banding.  As summarized in Fig.  6 D, 
64% of the total fluorescent spots found on chromosome 12 
were clustered on the p13-p12  bands. 
Discussion 
This study describes the cloning and sequencing of the 
cDNA encoding the human early lymphocyte activation an- 
tigen CD69.  The molecular doning of CD69 antigen was 
achieved  by a combined strategy that included partial protein 
sequencing and PCR techniques. Confirmation that the cloned 
cDNA indeed represents CD69 is based on several lines of 
evidence. (a) The predicted amino acid sequence encoded by 
the OKF is a protein with a molecular weight of 22,545, 
which is similar to the reported molecular weight (22,000- 
24,000)  of the deglycosylated native CD69 protein (6,  8); 
(b)  the four peptide  sequences obtained from the CD69- 
purified protein are found in the translated sequence of the 
isolated gene; and (c) transfection of  COS cells with the doned 
CD69  cDNA shows that a disulfide-linked homodimer of 
the expected molecular weight under both reducing and non- 
reducing SDS-PAGE  conditions can be precipitated by sev- 
eral anti-CD69 mAbs that are directed against extracellular 
and intraceUular epitopes of the molecule (8). 
The ORF of CD69 cDNA predicts a 199-amino add poly- 
peptide with a type II transmembrane topology. The extracel- 
lular COOH-terminal domain possesses an available site for 
N-linked glycosylation as proposed for the native protein (6, 
8).  Previous studies of cell protease treatments revealed the 
presence of a CD69 pronase-resistant peptide of 16,000 Mr 
that lost the external epitopes, suggesting that the native pro- 
tein could be predominantly an intracellular protein (8). How- 
ever, it is now evident that CD69  indeed possesses  a large 
protease-resistant fragment in the extracellular region of the 
protein. This is in accordance with the observations that the 
purified glycosylated native protein was refractory to protease 
fragmentation, and that most of the currently used proteases 
failed to cleave the deglycosylated protein without previous 
SDS denaturation (8).  Taken together, these findings show 
that the majority of the antigenic sites recognized by different 
CD69 antibodies, including those with agonistic properties, 
would be located in the terminal fragment of the external 
domain, likely into the lectin domain. 
The regulation of the expression of CD69 in PBL appears 
to be of remarkable interest. Like other immediate early genes 
(45, 46),  the CD69 gene displays a rapid and transient ex- 
pression, followed by a rapid decay and degradation at the 
RNA level. The presence of  reiterate rapid degradation signals 
(47)  at the 3' end of CD69  mKNA may explain its rapid 
turnover. This tight regulation ensures the transient activa- 
tion of this gene and contributes to prevent the uncontrolled 
expression of the CD69 receptor implicated in lymphocyte 
proliferation. The pattern of CD69 gene expression closely 
resembles that of  proto-oncogenes and most cytokines  in lym- 
phocytes, and it is clearly distinct from that of other lym- 
phocyte activation molecules such as the IL-2 and transferrin 
receptors, which exhibit a slower kinetics of both KNA in- 
duction and degradation (1, 48). However, the expression of 
the CD69 protein on lymphocyte cell surface persisted for 
longer periods of time. This may be attributed to the high 
stability of the CD69 glycoprotein, and its refractoriness to 
proteolytic mechanisms as discussed above.  Whatever  the 
mechanisms regulating the expression of the CD69 gene are, 
they remain unknown and deserve further investigation. 
Comparison of CD69 cDNA with known sequences in- 
dicates that the extracellular region of CD69 is characterized 
by the presence of a C-type animal lectin domain with similar 
membrane orientation and protein sequence as those found 
in members of this lectin family. Hence, CD69 is related to 
a growing family of type II transmembrane receptors, which 
includes the gene families coding for human NKG2 (35), rat 
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Figure  6.  Chromosomal local- 
ization of  the CD69 gene. (A) PCR 
analysis of  DNA from human, ham- 
ster, and a set of human-hamster 
hybrids from the panel of BIOS- 
MAI  rrM. PCK reactions were per- 
formed using AIM I and 3 primers. 
0ane M) molecular  weight markers; 
(lane 1) hamster; (lane 2) human; 
(hnes 3-8) hybrids containing the 
following  human  chromosomes: 
(lane 3) chromosome 3;  (lane 4) 
chromosomes  3,  5,  12,  14,  20 
(40%), and 22 (25%), Y; (lane 5) 
chromosomes 5, 11, 12 (45%), 14, 
19, 21, and 22; (lane 6) chromo- 
somes, 1 (60%), 5, 13, 14, 18, and 
19; (lane 7) chromosomes  1, DS, 13, 
19, 21, and 22; (lane 8) chromo- 
somes 5 and 20. (B) Southern blot 
analysis of  PCR products amplified 
in A. The corresponding genomic 
fragment of CD69 was used as a 
specific random primer probe la- 
baled with  ~x-pzP]dCTP. A faint 
specific band can be detected after 
longer autoradiography  exposure in 
lane 5. (C) Fluorescence  in situ hy- 
bridization on human metaphases 
with a digoxigenin-labeled 15-kb 
genomic  DNA probe  for the human 
CD69  gene. Arrows indicate the 
specific site of hybridization of the 
CD69 probe  detected  by rhodamine- 
labded antidigoxigenin antibodies 
on DAPI counterstained chromo- 
somes. Fluorescent  spots are located 
at 12 p13-p12. (Inset) Examples of 
DAPI and GTG-banding chromo- 
some 12 from other ceils. (D) As- 
signment of the CD69 gene to 12 
p13-p12. The idiogram of  chromo- 
some 12 schematically  indicates the 
distribution of  fluorescent spots for 
the CD69 locus. 
NKR-P1 (36), and mouse NKR-P1 (37, 49), which show 
preferential  expression on LAK and NK cells. Other type 
II lectin cell surface receptors with structural similarities to 
CD69 are the mouse Ly 49 (42, 43) expressed by activated 
T cells, the CD23 low at~nity Fce receptor, present on acti- 
vated B cells and monocytes (38-40,  50),  and the hepatic 
asialoglycoprotein  receptors  implicated  in the clearance of 
plasma glycoproteins (41). Interestingly, the intracellular do- 
main of CD69 maintains  a certain degree of sequence ho- 
mology only with members of the lectin superfamily  expressed 
by leukocytes, but not with lectin receptors found in hepa- 
tocytes. 
Our studies by PCR analysis on somatic cell hybrid DNA 
demonstrate that the human CD69 gene is located on chro- 
mosome 12, in accordance with previous serological analysis 
of human-mouse somatic cell hybrids (51).  In addition, we 
have regionally mapped the CD69 gene to the distal region 
of the short arm of chromosome 12, bands p13-p12. Interest- 
ingly, the genes coding for Ly 49 and NKI.1 antigens are 
closely linked within the distal portion of mouse chromo- 
some 6, which is the homologous region with human chro- 
mosome 12p (52, 53). The possibility of a gene cluster en- 
coding this family of C-lectin receptors expressed  by activated 
T  lymphocytes and NK cells raises important questions  in 
terms of both the regulation of gene expression and their 
function in leukocyte activation. 
The CD69 protein shares structural and functional features 
with NK-specific receptors encoded by human NKG2 and 
rat and mouse NKR-P1 (53). All are disulfide-linked dimers 
with a similar molecular size whose expression is either in- 
duced or enhanced during activation of T lymphocytes and 
NK cells. Although differentially  expressed among leukocytes, 
all these molecules act as triggering structures. The activating 
effect of antibodies specific for the mouse and human CD69 
antigen in stimulating redirected  target cell lysis by IL-2- 
activated NK cells (22, 23) is similar to that described with 
544  Molecular  Cloning of the CD69 Activation Antigen antibodies specific for other members of the family such as 
mouse NKI.1 and rat NKR-P1 antigens (22,  54).  Further- 
more, CD69 antibodies are capable of inducing intracellular 
signals,  including mobilization of intracellular calcium and 
T cell proliferation in conjunction with suboptimal doses of 
phorbol esters (4, 19). Similarly, NKR-P1 also functions as 
an activating molecule on rat NK cells  stimulating phos- 
phoinositide turnover and rise of intracellular calcium (55). 
CD69 also displays common functional properties with the 
type II lectin Fce receptor CD23. The CD23 receptor, like 
CD69,  is involved in lymphocyte proliferation and can be 
upregnlated by cytokines (56). Moreover, a proteolytic soluble 
fragment of CD23 containing the lectin domain with mito- 
genic activity for B lymphocytes has been described (56). CD23 
acts as a receptor for the Fc portion of IgE and, additionally, 
its interaction with the B cell antigen CD21 has recently been 
reported (57).  The region involved in the interaction with 
IgE has been demonstrated to correspond almost exactly to 
the domain homologous with animal lectins (58).  The in- 
tegrity of the invariant cysteines is absolutely required for 
IgE binding (58). 
The expression of a C-type lectin domain by the members 
of this superfamily of transmembrane receptors suggests their 
possible interaction with carbohydrates in a calcium-dependent 
manner. Evidence for such a role has been described for the 
CD23 member of the family (59).  In addition, studies sup- 
porting the possibility that carbohydrate structures are in- 
volved in recognition events mediated by NK cells have been 
reported (60).  However, the identification of such putative 
carbohydrate ligands is required to elucidate the functional 
role of the lectin domain of CD69 and the other members 
of this family of signal transmembrane receptors. 
It is important to remark that although CD69 is absent 
on circulating PBL, it is expressed at remarkably high levels 
in the majority of T  cells in the inflammatory infiltrates of 
several human diseases. Thus, CD69 expression has been de- 
tected in T lymphocytes of synovial membrane and synovial 
fluid from rheumatoid arthritis patients (12),  as well as on 
CD8 + T ceils in infiltrates of virus-induced chronic inflam- 
matory liver diseases (11). In addition, CD69 is also expressed 
by certain CD4 + T  cells in the germinal centers of normal 
lymph nodes and by a  small subpopulation  of medullary 
thymocytes (13, 14). Therefore, it could be hypothesized that 
CD69 functions as an immediate early receptor that would 
be required for tissue positioning and localization,  and/or 
for migration toward sites of inflammation. Conceivably, the 
expression of a C-type lectin domain externally exposed on 
CD69 may enable its interaction with carbohydrate moities, 
allowing T cell migration across the endothelial cell layer and 
different tissue components. The molecular characterization 
of the CD69 protein and its adscription to this superfamily 
of C-lectin signaling molecules provide new insights regarding 
the possible functional role of these cell surface transmem- 
brane receptors. 
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